The FDA has approved a life-changing therapy for Diabetes. It says an antibody called Teplizumab can delay the onset of Type 1 Diabetes. Priyanka Sharma reports.

Gravitas: FDA approves life-changing therapy for Diabetes

AstraZeneca's COVID-19 antibody combination Evusheld has the properties to neutralise Coronavirus variants of Omicron, including the highly-contagious BA.2 sub-variant, the pharmaceutical company said after conducting an independent lab study.

The study done by the Washington University School of Medicine in St. Louis showed that the therapy reduced the amount of virus detected in samples of all tested Omicron subvariants in mice lungs, the London-listed drugmaker said in a statement on Monday.

The study has yet to be peer reviewed, according to Reuters.

Evusheld, was tested against the BA.1, BA.1.1, and BA.2 subvariants of Omicron and it was also shown to limit inflammation in the lungs.

The drug is a combination of two long-acting antibodies derived from B-cells donated by patients recovering from COVID-19.

"These important data show that Evusheld reduced viral burden and limited inflammation caused by Omicron," AstraZeneca Vice President John Perez in a statement.

"The findings further support Evusheld as a potential important option to help protect vulnerable patients such as the immunocompromised who could face poor outcomes if they were to become infected with COVID-19."

The study conducted on mice demonstrated Evusheld significantly reduced the viral burden and limited inflammation in the lungs for all three sub-variants, the company said.

The antibody cocktail is approved in many European countries and the United States, which gave the nod in December.

The World Health Organisation said last week figures showing a global rise in COVID-19 cases could herald a much bigger problem, as the Omicron and BA.2 variants spread amid the easing of restrictions and testing.

“WHO will continue to closely monitor the BA.2 lineage as part of Omicron and requests countries to continue to be vigilant, to monitor and report sequences, as well as to conduct independent and comparative analyses of the different Omicron sublineages,” it said in a statement.

(With inputs from agencies)

AstraZeneca's COVID-19 antibody combination Evusheld has the properties to neutralise Coronavirus variants of Omicron, including the highly-contagious BA.2 sub-variant, the pharmaceutical company said after conducting an independent lab study.

AstraZeneca's COVID-19 antibody combination Evusheld has the properties to neutralise Coronavirus variants of Omicron, including the highly-contagious BA.2 sub-variant, the pharmaceutical company said after conducting an independent lab study. The study done by the Washington University School of Medicine in St. Louis showed that the therapy reduced the amount of virus detected in samples of all tested Omicron subvariants in mice lungs, the London-listed drugmaker said in a statement on Monday. The study has yet to be peer reviewed, according to Reuters. Evusheld, was tested against the BA.1, BA.1.1, and BA.2 subvariants of Omicron and it was also shown to limit inflammation in the lungs. The drug is a combination of two long-acting antibodies derived from B-cells donated by patients recovering from COVID-19. "These important data show that Evusheld reduced viral burden and limited inflammation caused by Omicron," AstraZeneca Vice President John Perez in a statement. "The findings further support Evusheld as a potential important option to help protect vulnerable patients such as the immunocompromised who could face poor outcomes if they were to become infected with COVID-19." The study conducted on mice demonstrated Evusheld significantly reduced the viral burden and limited inflammation in the lungs for all three sub-variants, the company said. The antibody cocktail is approved in many European countries and the United States, which gave the nod in December. The World Health Organisation said last week figures showing a global rise in COVID-19 cases could herald a much bigger problem, as the Omicron and BA.2 variants spread amid the easing of restrictions and testing. “WHO will continue to closely monitor the BA.2 lineage as part of Omicron and requests countries to continue to be vigilant, to monitor and report sequences, as well as to conduct independent and comparative analyses of the different Omicron sublineages,” it said in a statement. (With inputs from agencies)

AstraZeneca claims its COVID-19 antibody concoction can neutralise BA.2 Omicron sub-variant

In what comes as China's first specialised treatment against Covid-19, the government has approved its Covid drug. An official note on Wednesday read China's National Medical Products Administration said it has granted "emergency approval" for monoclonal antibody treatment.

The monoclonal antibodies are proteins that have been designed to attach a specific target. In the case of Covid, the target will be the spike protein of SARS-CoV-2, which is used by the virus to enter human cells.&nbsp;

The therapy has been co-developed by Tsinghua University, the Third People's Hospital of Shenzhen and Brii Biosciences.

According to a statement issued by Tsinghua University, the trials showed that the therapy could reduce the risk of hospitalisation and death by around 80 per cent.

<a href="https://www.wionews.com/world/covid-in-a-first-fda-authorises-astrazenecas-evusheld-as-a-purely-preventative-treatment-435315">Also read |&nbsp;Covid: In a first, FDA authorises AstraZeneca's Evusheld as a purely preventative treatment</a>

As per the drug authority, this treatment involves a combination of two drugs, which are administered through injections.&nbsp;Also, they can be used to treat certain cases that can get severe.

Meanwhile, the US Food and Drug Administration has issued an emergency use authorisation for AstraZeneca's Evusheld to prevent people from the deadly coronavirus. Evusheld comprises two types of synthetic antibodies - tixagevimab and cilgavimab. It is given as two intramuscular injections.

"The product is only authorised for those individuals who are not currently infected with the SARS-CoV-2 virus and who have not recently been exposed to an individual infected with SARS-CoV-2," read the statement issued by FDA. This is the first time that the FDA has given emergency authorisation for purely preventative treatment.&nbsp;

(With inputs from agencies)

In what comes as China's first specialised treatment against Covid-19, the government has approved its Covid drug. An official note on Wednesday read China's National Medical Products Administration said it has granted "emergency approval" for monoclonal antibody treatment.

In what comes as China's first specialised treatment against Covid-19, the government has approved its Covid drug. An official note on Wednesday read China's National Medical Products Administration said it has granted "emergency approval" for monoclonal antibody treatment. The monoclonal antibodies are proteins that have been designed to attach a specific target. In the case of Covid, the target will be the spike protein of SARS-CoV-2, which is used by the virus to enter human cells. The therapy has been co-developed by Tsinghua University, the Third People's Hospital of Shenzhen and Brii Biosciences. According to a statement issued by Tsinghua University, the trials showed that the therapy could reduce the risk of hospitalisation and death by around 80 per cent. Also read | Covid: In a first, FDA authorises AstraZeneca's Evusheld as a purely preventative treatment As per the drug authority, this treatment involves a combination of two drugs, which are administered through injections. Also, they can be used to treat certain cases that can get severe. Meanwhile, the US Food and Drug Administration has issued an emergency use authorisation for AstraZeneca's Evusheld to prevent people from the deadly coronavirus. Evusheld comprises two types of synthetic antibodies - tixagevimab and cilgavimab. It is given as two intramuscular injections. "The product is only authorised for those individuals who are not currently infected with the SARS-CoV-2 virus and who have not recently been exposed to an individual infected with SARS-CoV-2," read the statement issued by FDA. This is the first time that the FDA has given emergency authorisation for purely preventative treatment. (With inputs from agencies)

Covid: China grants emergency approval for its first Monoclonal antibody drug

The World Health Organization (WHO) on Friday recommended the synthetic&nbsp;antibody&nbsp;treatment&nbsp;Regeneron for&nbsp;Covid-19, but only in&nbsp;patients&nbsp;with specific health profiles. &nbsp;

Persons with non-severe&nbsp;Covid-19&nbsp;who&nbsp;are nonetheless at&nbsp;high risk&nbsp;of hospitalisation can take the&nbsp;antibody&nbsp;combo, as should critically ill&nbsp;patients&nbsp;unable to mount an adequate immune response, according to a&nbsp;WHO&nbsp;finding published in BMJ.

Regeneron is only the third&nbsp;treatment&nbsp;for&nbsp;Covid&nbsp;to be recommended by the global health authority, which added it to its "living&nbsp;WHO&nbsp;guideline" on drugs for&nbsp;Covid-19.

In July,&nbsp;WHO&nbsp;gave the nod to a class of drugs that act to suppress a dangerous overreaction of the immune system to the SARS-CoV-2 virus that causes&nbsp;Covid.&nbsp;

These medicines work well in tandem with corticosteroids, which were first recommended by&nbsp;WHO&nbsp;for use in&nbsp;Covid&nbsp;patients&nbsp;in September 2020.

The Regeneron cocktail of synthetic antibodies, casirivimab and imdevimab, has been found to reduce the risk of hospitalisation for unvaccinated, elderly or immunosuppressed&nbsp;patients&nbsp;with&nbsp;Covid, according to three clinical trials that have yet to be peer reviewed, according to the BMJ.&nbsp;

<a href="https://www.wionews.com/science/footprints-reveal-humans-arrived-in-americas-before-end-of-ice-age-415362">Also read |&nbsp;Footprints reveal humans arrived in Americas before end of Ice Age</a>

For the second category of patient covered by the new&nbsp;WHO&nbsp;recommendation, another trial has reported a reduced number of deaths, and cases requiring mechanical ventilation, in&nbsp;patients&nbsp;taking the drugs.

"For all other&nbsp;covid-19&nbsp;patients, any benefits of this&nbsp;antibody&nbsp;treatment&nbsp;are unlikely to be meaningful," the&nbsp;WHO&nbsp;concluded.

Designed by biotech firm Regeneron and marketed by pharmaceutical giant Roche under the name Ronapreve, the&nbsp;treatment&nbsp;was given to former US President Donald Trump during his brush with coronavirus.&nbsp;

When used together, the monoclonal antibodies casirivimab and imdevimab bind to the SARS-CoV-2 spike protein, neutralising the virus’s ability to infect cells.

The World Health Organization "welcomes the addition of another therapeutic&nbsp;to the world’s arsenal against&nbsp;COVID-19", but expressed concern about the impact of high prices on health inequality.

"Given the high cost and low availability of the combination therapy, [global health agency] UNITAID is negotiating with Roche Pharmaceutical ... for lower prices and equitable distribution across all regions, especially in low- and middle-income countries,"&nbsp;WHO&nbsp;said in a separate statement.

"WHO&nbsp;is also in discussions with the company for a donation and distribution of the drug through UNICEF."

The UN health authority also called on other manufacturers to submit "bio-similar" versions of the drug for approval.

In July, Japan had become the first country to fully approve Regeneron's&nbsp;antibody&nbsp;treatment&nbsp;for&nbsp;patients&nbsp;with mild to moderate&nbsp;Covid-19.

The&nbsp;antibody&nbsp;combination has been authorised for emergency or temporary pandemic use in a number of countries and regions, including the European Union, United States, India, Switzerland and Canada.

The World Health Organization (WHO) on Friday recommended the synthetic antibody treatment Regeneron for Covid-19, but only in patients with specific health profiles.

The World Health Organization (WHO) on Friday recommended the synthetic antibody treatment Regeneron for Covid-19, but only in patients with specific health profiles. Persons with non-severe Covid-19 who are nonetheless at high risk of hospitalisation can take the antibody combo, as should critically ill patients unable to mount an adequate immune response, according to a WHO finding published in BMJ. Regeneron is only the third treatment for Covid to be recommended by the global health authority, which added it to its "living WHO guideline" on drugs for Covid-19. In July, WHO gave the nod to a class of drugs that act to suppress a dangerous overreaction of the immune system to the SARS-CoV-2 virus that causes Covid. These medicines work well in tandem with corticosteroids, which were first recommended by WHO for use in Covid patients in September 2020. The Regeneron cocktail of synthetic antibodies, casirivimab and imdevimab, has been found to reduce the risk of hospitalisation for unvaccinated, elderly or immunosuppressed patients with Covid, according to three clinical trials that have yet to be peer reviewed, according to the BMJ. Also read | Footprints reveal humans arrived in Americas before end of Ice Age For the second category of patient covered by the new WHO recommendation, another trial has reported a reduced number of deaths, and cases requiring mechanical ventilation, in patients taking the drugs. "For all other covid-19 patients, any benefits of this antibody treatment are unlikely to be meaningful," the WHO concluded. Designed by biotech firm Regeneron and marketed by pharmaceutical giant Roche under the name Ronapreve, the treatment was given to former US President Donald Trump during his brush with coronavirus. When used together, the monoclonal antibodies casirivimab and imdevimab bind to the SARS-CoV-2 spike protein, neutralising the virus’s ability to infect cells. The World Health Organization "welcomes the addition of another therapeutic to the world’s arsenal against COVID-19", but expressed concern about the impact of high prices on health inequality. "Given the high cost and low availability of the combination therapy, [global health agency] UNITAID is negotiating with Roche Pharmaceutical ... for lower prices and equitable distribution across all regions, especially in low- and middle-income countries," WHO said in a separate statement. "WHO is also in discussions with the company for a donation and distribution of the drug through UNICEF." The UN health authority also called on other manufacturers to submit "bio-similar" versions of the drug for approval. In July, Japan had become the first country to fully approve Regeneron's antibody treatment for patients with mild to moderate Covid-19. The antibody combination has been authorised for emergency or temporary pandemic use in a number of countries and regions, including the European Union, United States, India, Switzerland and Canada.

WHO backs antibody treatment for high-risk COVID-19 patients

Before Juhi Singh, 46, who owns a high-end wellness center on the Upper East Side, jetted off to the Amalfi Coast last month, she packed her bathing suits and left her 10-year-old son with his grandmother.

Her personal driver also took her to Sollis Healthcare, a concierge medical service in Manhattan, to measure her antibodies for the coronavirus. She received the Johnson &amp; Johnson vaccine in February, and wanted to see if her immunity was still robust before joining friends at a five-star resort overlooking the Tyrrhenian Sea.

“I wouldn’t go on a trip without my antibodies,” Singh said. “It’s nerve-wracking, but my numbers have been good.”

An email arrived 24 hours later with her results: 14.8 arbitrary units per milliliter. Although medical experts warn that an antibody count cannot tell if somebody is protected against the virus, patients have been reading into the numbers anyway. “Mine have dipped a little bit, but I know my vaccine is still working, and I am still protected,” Singh said.

Antibody testing on a monthly or regular basis has become a common practice among certain members of the nervous affluent class. “A lot of my patients and some of my friends are counting their antibodies,” Singh said. “It’s the Upper East Side, the Hamptons circles. It’s like dinner conversation at this point. It almost feels like counting calories.”

Medical concierge services, including Sollis, have started offering antibody tests as a perk to clients. “I check them for people daily,” said Dr. Scott Braunstein, the medical director of Sollis’ office in Los Angeles.

My Concierge MD, an upscale health care practice in Beverly Hills, California, has set up a drive-through where clients, including celebrities and Hollywood executives, can get tested without getting out of their G-Wagons and Teslas. “We do it with a finger prick,” said Dr. David Nazarian, who runs the practice. “Let’s just say with delta, the test sites are busy right now.”

But Arthur Caplan, a professor of bioethics at New York University’s Grossman School of Medicine, is concerned about the overuse of antibody tests. “The doctors who are promoting them are not promoting good science,” Caplan said. “I think they are putting their patient at risk, because there are no agreed upon antibody levels.”

Some people check their antibodies because they are immunocompromised or are living with high-risk individuals. (Singh is the caretaker for her 91-year-old grandmother.) Others do it for peace of mind before taking an international flight or attending a gala.

Others just want to be armed with more information about their medical status, something that has become normalized in the era of health monitoring apps. “Our patients are very analytical,” said Dr. Alan Viglione, who runs Montecito Concierge Medicine, a private health care provider in Montecito, California. “We have a lot of patients who want to know their numbers. It’s become a new trend to know what your antibodies are.”

Patients who get a low antibody count may decide to change their behaviors or “life choices,” Braunstein said. “They might decide to skip that wedding. They might take extra precautions.”

Some may opt to get a booster shot. Although the Food and Drug Administration has only authorized booster shots for those who are immunocompromised, there is some evidence that more than 1 million Americans have already received unauthorized third doses.

One medical concierge service was even encouraging high-risk patients to check their antibody levels before getting a booster — something that no public health agency has recommended.

To Test or Not to Test

Getting an antibody test (also known as a serology test) is a relatively easy procedure. Blood, drawn through a finger prick or through a vein, is screened for antibody proteins created by the immune system to fight infection or after vaccination. Antibody tests do not check for the virus itself and cannot be used to diagnose whether someone has Covid.

“It’s a simple blood test, and we see the results the next day because there are a number of large labs across the country doing it,” Braunstein said. “It isn’t overly expensive. Most insurances will cover it, but if they don’t it’s about $100 to 200.”

But the results offer limited information. Current tests only look for antibodies for SARS-CoV-2, the virus that causes COVID-19, and not for T cells, which play an important role in the body’s immune response.

It is also not clear what the antibody count means. For starters, different tests measure the strength of the antibodies differently. A person who gets tested by Sollis, for example, may get a count of 20 or higher, while a different lab may give a result of 270 or higher. (A person without antibodies would get a negative result.)

A higher number may not necessarily confer great immunity. “We don’t have exact data on what a 4 means versus a 15,” Braunstein said. “You can’t specifically say that you are a 9, and I am a 8, so you are more protected than me.”

Indeed, the FDA does not recommend that people use antibody tests to gauge immunity and, in fact, warns of its potential risk. People who receive a high antibody count may take fewer precautions, such as mask wearing, that could result in infection or spread. (Braunstein said that “all of our patients are informed of this recommendation and advised to follow all CDC recommended safety measures, regardless of the test result.”)

“It can give you a false sense of security,” said Caplan, who leads NYU’s division of medical ethics. “They might say, ‘I got my antibody test, so I am not going to wear a mask or I am going to that concert, because I know I’m immune,’ which in fact they don’t know.”

Caplan is also concerned that people might use their antibody count as an excuse to skip a booster vaccination when the time comes. “Even if you have antibodies, it doesn’t mean you have them sufficient enough to fight off new variants,” he said.

‘Why Wouldn’t I?’

Still, antibody counting has become a practice among the wealthy who regard their health as a full-time undertaking, where no medical test is too insignificant and no medical resource too expensive.

“People read articles and get on the internet and do research and want to do tests,” Caplan said. “But it is up to the doctor to filter that and calm me down so I don’t spend money on useless or harmful things.”

Medical concierge services, he argues, often do the opposite — that is, cater to their patients’ wishes. “The problem is when you are a concierge practice, you have to honor what they want because they are paying you money to do what they want,” Caplan said.

The poor, he said, often avoid medical tests because they are scared they will lose their health insurance or job if they get a bad result. “If it turns out you have low antibodies, all of a sudden you might think, ‘I can’t tell anybody about this, because my boss won’t let me come into work,’” Caplan said. “The penalties for knowing more about bad health are not problems the rich face.”

That is certainly the case with affluent people who are counting their antibodies.

“With this delta variant, I want to know where I stand,” said Terry Cohen, 62, a real estate agent in the Hamptons who works with high-end properties. “I want to understand what is happening in my body.”

Cohen, who lives in Sagaponack, New York, received two doses of the AstraZeneca vaccine while in Anguilla last winter. She felt protected until the delta variant surged in July. She also wondered why people her age in Israel were getting booster shots if the vaccines were still effective, and why she was hearing of so many breakthrough cases in her social circle.

News about how much protection the vaccines offer also kept changing. “Whatever one says on Monday the following Monday needs updating,” she said.

So she began checking her antibodies about once a month. “Why wouldn’t I?” Cohen said. “We have the ability to check them, and it’s good data for me to know. I had plenty last time and it makes me feel better, at least for this moment, knowing I am protected.”

As fears mount, concierge doctors are offering other ways to gauge immunity.

Sollis now offers a commercially available test for $200 that checks for T cells. “The test is much more difficult because there are only a few labs in the country doing this,” Dr. Braunstein said. “There is a seven-day turnaround with results, but we think it’s worth it.”

“I have had two or three clients ask for T cell tests,” added Viglione of Montecito. “Right now only specialty labs will do it, but in a month or so I think it will be much more common. It’s trendy to have a lot of personal data.”

Before Juhi Singh, 46, who owns a high-end wellness center on the Upper East Side, jetted off to the Amalfi Coast last month, she packed her bathing suits and left her 10-year-old son with his grandmother.

Before Juhi Singh, 46, who owns a high-end wellness center on the Upper East Side, jetted off to the Amalfi Coast last month, she packed her bathing suits and left her 10-year-old son with his grandmother. Her personal driver also took her to Sollis Healthcare, a concierge medical service in Manhattan, to measure her antibodies for the coronavirus. She received the Johnson & Johnson vaccine in February, and wanted to see if her immunity was still robust before joining friends at a five-star resort overlooking the Tyrrhenian Sea. “I wouldn’t go on a trip without my antibodies,” Singh said. “It’s nerve-wracking, but my numbers have been good.” An email arrived 24 hours later with her results: 14.8 arbitrary units per milliliter. Although medical experts warn that an antibody count cannot tell if somebody is protected against the virus, patients have been reading into the numbers anyway. “Mine have dipped a little bit, but I know my vaccine is still working, and I am still protected,” Singh said. Antibody testing on a monthly or regular basis has become a common practice among certain members of the nervous affluent class. “A lot of my patients and some of my friends are counting their antibodies,” Singh said. “It’s the Upper East Side, the Hamptons circles. It’s like dinner conversation at this point. It almost feels like counting calories.” Medical concierge services, including Sollis, have started offering antibody tests as a perk to clients. “I check them for people daily,” said Dr. Scott Braunstein, the medical director of Sollis’ office in Los Angeles. My Concierge MD, an upscale health care practice in Beverly Hills, California, has set up a drive-through where clients, including celebrities and Hollywood executives, can get tested without getting out of their G-Wagons and Teslas. “We do it with a finger prick,” said Dr. David Nazarian, who runs the practice. “Let’s just say with delta, the test sites are busy right now.” But Arthur Caplan, a professor of bioethics at New York University’s Grossman School of Medicine, is concerned about the overuse of antibody tests. “The doctors who are promoting them are not promoting good science,” Caplan said. “I think they are putting their patient at risk, because there are no agreed upon antibody levels.” Some people check their antibodies because they are immunocompromised or are living with high-risk individuals. (Singh is the caretaker for her 91-year-old grandmother.) Others do it for peace of mind before taking an international flight or attending a gala. Others just want to be armed with more information about their medical status, something that has become normalized in the era of health monitoring apps. “Our patients are very analytical,” said Dr. Alan Viglione, who runs Montecito Concierge Medicine, a private health care provider in Montecito, California. “We have a lot of patients who want to know their numbers. It’s become a new trend to know what your antibodies are.” Patients who get a low antibody count may decide to change their behaviors or “life choices,” Braunstein said. “They might decide to skip that wedding. They might take extra precautions.” Some may opt to get a booster shot. Although the Food and Drug Administration has only authorized booster shots for those who are immunocompromised, there is some evidence that more than 1 million Americans have already received unauthorized third doses. One medical concierge service was even encouraging high-risk patients to check their antibody levels before getting a booster — something that no public health agency has recommended. To Test or Not to Test Getting an antibody test (also known as a serology test) is a relatively easy procedure. Blood, drawn through a finger prick or through a vein, is screened for antibody proteins created by the immune system to fight infection or after vaccination. Antibody tests do not check for the virus itself and cannot be used to diagnose whether someone has Covid. “It’s a simple blood test, and we see the results the next day because there are a number of large labs across the country doing it,” Braunstein said. “It isn’t overly expensive. Most insurances will cover it, but if they don’t it’s about $100 to 200.” But the results offer limited information. Current tests only look for antibodies for SARS-CoV-2, the virus that causes COVID-19, and not for T cells, which play an important role in the body’s immune response. It is also not clear what the antibody count means. For starters, different tests measure the strength of the antibodies differently. A person who gets tested by Sollis, for example, may get a count of 20 or higher, while a different lab may give a result of 270 or higher. (A person without antibodies would get a negative result.) A higher number may not necessarily confer great immunity. “We don’t have exact data on what a 4 means versus a 15,” Braunstein said. “You can’t specifically say that you are a 9, and I am a 8, so you are more protected than me.” Indeed, the FDA does not recommend that people use antibody tests to gauge immunity and, in fact, warns of its potential risk. People who receive a high antibody count may take fewer precautions, such as mask wearing, that could result in infection or spread. (Braunstein said that “all of our patients are informed of this recommendation and advised to follow all CDC recommended safety measures, regardless of the test result.”) “It can give you a false sense of security,” said Caplan, who leads NYU’s division of medical ethics. “They might say, ‘I got my antibody test, so I am not going to wear a mask or I am going to that concert, because I know I’m immune,’ which in fact they don’t know.” Caplan is also concerned that people might use their antibody count as an excuse to skip a booster vaccination when the time comes. “Even if you have antibodies, it doesn’t mean you have them sufficient enough to fight off new variants,” he said. ‘Why Wouldn’t I?’ Still, antibody counting has become a practice among the wealthy who regard their health as a full-time undertaking, where no medical test is too insignificant and no medical resource too expensive. “People read articles and get on the internet and do research and want to do tests,” Caplan said. “But it is up to the doctor to filter that and calm me down so I don’t spend money on useless or harmful things.” Medical concierge services, he argues, often do the opposite — that is, cater to their patients’ wishes. “The problem is when you are a concierge practice, you have to honor what they want because they are paying you money to do what they want,” Caplan said. The poor, he said, often avoid medical tests because they are scared they will lose their health insurance or job if they get a bad result. “If it turns out you have low antibodies, all of a sudden you might think, ‘I can’t tell anybody about this, because my boss won’t let me come into work,’” Caplan said. “The penalties for knowing more about bad health are not problems the rich face.” That is certainly the case with affluent people who are counting their antibodies. “With this delta variant, I want to know where I stand,” said Terry Cohen, 62, a real estate agent in the Hamptons who works with high-end properties. “I want to understand what is happening in my body.” Cohen, who lives in Sagaponack, New York, received two doses of the AstraZeneca vaccine while in Anguilla last winter. She felt protected until the delta variant surged in July. She also wondered why people her age in Israel were getting booster shots if the vaccines were still effective, and why she was hearing of so many breakthrough cases in her social circle. News about how much protection the vaccines offer also kept changing. “Whatever one says on Monday the following Monday needs updating,” she said. So she began checking her antibodies about once a month. “Why wouldn’t I?” Cohen said. “We have the ability to check them, and it’s good data for me to know. I had plenty last time and it makes me feel better, at least for this moment, knowing I am protected.” As fears mount, concierge doctors are offering other ways to gauge immunity. Sollis now offers a commercially available test for $200 that checks for T cells. “The test is much more difficult because there are only a few labs in the country doing this,” Dr. Braunstein said. “There is a seven-day turnaround with results, but we think it’s worth it.” “I have had two or three clients ask for T cell tests,” added Viglione of Montecito. “Right now only specialty labs will do it, but in a month or so I think it will be much more common. It’s trendy to have a lot of personal data.”

Some rich people are counting their antibodies ‘like calories’

From containing the spread of virus to vaccinating people, Israel has been a step ahead of majority of the other countries in handling the coronavirus pandemic. Carrying that achievement forward, Israel has now launched an antibody test for children as young as three years old.

The antibody testing system has been launched to collect information about the number of unvaccinated children who might have developed protection against coronavirus. The process has started at a time when the students are gearing up to return to schools for a new academic year.

Also read |&nbsp;<a data-ctorig="https://www.wionews.com/world/israels-pm-bennett-receives-covid-19-booster-shot-as-infections-surge-407187" data-cturl="https://www.google.com/url?client=internal-element-cse&amp;cx=006054055338965708568:09spwrlibei&amp;q=https://www.wionews.com/world/israels-pm-bennett-receives-covid-19-booster-shot-as-infections-surge-407187&amp;sa=U&amp;ved=2ahUKEwjIwdPu1MTyAhXw3jgGHdTXDj0QFjAJegQIABAC&amp;usg=AOvVaw2IIxmZMykwTOBa9nOZE0po" dir="ltr" href="https://www.wionews.com/world/israels-pm-bennett-receives-covid-19-booster-shot-as-infections-surge-407187" target="_blank">Israel's&nbsp;PM Bennett receives COVID-19 booster shot</a>

Israel government has decided to call students back to school despite an increase in <a href="https://www.wionews.com/topics/coronavirus">coronavirus</a> cases in the country, caused by the Delta variant also dubbed as the ‘variant of concern’ by WHO.

The government is terming this as the "largest serological operation"&nbsp;and the officials are urging parents to bring their young children to the free test as soon as possible.

This test will be a free 15-minute test that will be conducted by a simple pin-prick process.

Also read |&nbsp;<a data-ctorig="https://www.wionews.com/world/israel-to-now-allow-gay-men-to-donate-blood-406891" data-cturl="https://www.google.com/url?client=internal-element-cse&amp;cx=006054055338965708568:09spwrlibei&amp;q=https://www.wionews.com/world/israel-to-now-allow-gay-men-to-donate-blood-406891&amp;sa=U&amp;ved=2ahUKEwiY1pmA1cTyAhXS4jgGHQfiBHI4ChAWMAB6BAgBEAI&amp;usg=AOvVaw3Nwb06XJpAO5XkU0IZ0I_K" dir="ltr" href="https://www.wionews.com/world/israel-to-now-allow-gay-men-to-donate-blood-406891" target="_blank">Israel&nbsp;to now allow gay men to donate blood</a>

Once the test is completed for all school-going children, the children who will have sufficient antibodies will not be asked to quarantine if they are exposed to a Covid patient. This will help make sure that the school year and classroom routine is not disrupted for children.

Israel government has decided to reopen the schools as experts believe that online teaching has negatively affected the students and has caused "emotional and social damage".

From containing the spread of virus to vaccinating people, Israel has been a step ahead of majority of the other countries in handling the coronavirus pandemic. Carrying that achievement forward, Israel has now launched an antibody test for children as young as three years old.

From containing the spread of virus to vaccinating people, Israel has been a step ahead of majority of the other countries in handling the coronavirus pandemic. Carrying that achievement forward, Israel has now launched an antibody test for children as young as three years old. The antibody testing system has been launched to collect information about the number of unvaccinated children who might have developed protection against coronavirus. The process has started at a time when the students are gearing up to return to schools for a new academic year. Also read | Israel's PM Bennett receives COVID-19 booster shot Israel government has decided to call students back to school despite an increase in coronavirus cases in the country, caused by the Delta variant also dubbed as the ‘variant of concern’ by WHO. The government is terming this as the "largest serological operation" and the officials are urging parents to bring their young children to the free test as soon as possible. This test will be a free 15-minute test that will be conducted by a simple pin-prick process. Also read | Israel to now allow gay men to donate blood Once the test is completed for all school-going children, the children who will have sufficient antibodies will not be asked to quarantine if they are exposed to a Covid patient. This will help make sure that the school year and classroom routine is not disrupted for children. Israel government has decided to reopen the schools as experts believe that online teaching has negatively affected the students and has caused "emotional and social damage".

Israel launches antibody testing programme for 3 year old children

AstraZeneca’s recent study of its monoclonal <a href="https://www.wionews.com/topics/coronavirus-vaccine">antibody treatment</a> has revealed that it failed to prevent the symptomatic coronavirus in people who had been recently exposed to the virus.

AZD7442 did reduce the risk of getting symptomatically infected by nearly 33 per cent, when compared to a placebo. However, it failed to meet the goal of preventing the symptomatic COVID-19 completely.

<a href="https://www.wionews.com/videos/us-crosses-grim-milestone-of-600000-covid-19-deaths-391601">WATCH |</a>

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/us-crosses-grim-milestone-of-600000-covid-19-deaths-391601/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

"While this trial did not meet the primary endpoint against symptomatic illness, we are encouraged by the protection seen in the PCR negative participants following treatment with AZD7442," Mene Pangalos, AstraZeneca executive vice president, said in a statement.

The study was performed on participants who were unvaccinated adults (older than 18 years of age) and had been surely exposed to a person who had been infected by the deadly coronavirus in the past eight days.

AstraZeneca has also started a study about the treatment in pre-exposed&nbsp;patients trial and for preventing more severe disease.

(With inputs from agencies)

AstraZeneca’s recent study of its monoclonal antibody treatment has revealed that it failed to prevent the symptomatic coronavirus in people who had been recently exposed to the virus.

AstraZeneca’s recent study of its monoclonal antibody treatment has revealed that it failed to prevent the symptomatic coronavirus in people who had been recently exposed to the virus. AZD7442 did reduce the risk of getting symptomatically infected by nearly 33 per cent, when compared to a placebo. However, it failed to meet the goal of preventing the symptomatic COVID-19 completely. WATCH | "While this trial did not meet the primary endpoint against symptomatic illness, we are encouraged by the protection seen in the PCR negative participants following treatment with AZD7442," Mene Pangalos, AstraZeneca executive vice president, said in a statement. The study was performed on participants who were unvaccinated adults (older than 18 years of age) and had been surely exposed to a person who had been infected by the deadly coronavirus in the past eight days. AstraZeneca has also started a study about the treatment in pre-exposed patients trial and for preventing more severe disease. (With inputs from agencies)

AstraZeneca's antibody fails in protecting exposed patients from COVID-19

According to Japan's health ministry, the number of COVID-19 infections in Tokyo may have jumped by nine-fold since last summer after anti-body tests were conducted as the country prepares to host the <a href="https://www.wionews.com/sports/olympics-will-happen-however-coronavirus-evolves-tokyo-2020-chief-360819">Olympic </a>games in July.

Watch:

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-tokyo-2020-president-refuses-to-resign-361426/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

The health ministry in a report said testing on people in Tokyo had revealed that 0.91 per cent had antibodies to the virus, compared with about 0.1 per cent in a similar study in June.

There was also witnessed spike in antibody rates in Osaka&nbsp;and Miyagi Prefecture.

Japan had earlier imposed a one-month emergency as the number of coronavirus cases surged, nine other areas including capital Tokoy was also put under restriction. Prime Minister Yoshihide Suga has approved the extension of the state of emergency until March 7.

"Hospitalisation will remain high for some time to come, that is why we have to continue with these measures," the Japan PM said, adding, "each and every one of us needs to change the way we act if we are to contain the virus's spread." However, PM Suga said the restrictions will be lifted before March 7 in prefectures where the virus situation improves.

Japan's government has insisted the Olympic games will go ahead as planned in July after it was postponed last year as the pandemic took hold worldwide.

The country's Parliament had passed a new law strengthening enforcement of its virus restrictions which included fine on bars and restaurants which defy closure request with just five months left for the pandemic-postponed summer Olympics in Tokyo.

Japan currently has over 390,000 coronavirus cases and 5,832 fatalities as it grapples with the virus.

According to Japan's health ministry, the number of COVID-19 infections in Tokyo may have jumped by nine-fold since last summer after anti-body tests were conducted as the country prepares to host the Olympic games in July.

According to Japan's health ministry, the number of COVID-19 infections in Tokyo may have jumped by nine-fold since last summer after anti-body tests were conducted as the country prepares to host the Olympic games in July. Watch: The health ministry in a report said testing on people in Tokyo had revealed that 0.91 per cent had antibodies to the virus, compared with about 0.1 per cent in a similar study in June. There was also witnessed spike in antibody rates in Osaka and Miyagi Prefecture. Japan had earlier imposed a one-month emergency as the number of coronavirus cases surged, nine other areas including capital Tokoy was also put under restriction. Prime Minister Yoshihide Suga has approved the extension of the state of emergency until March 7. "Hospitalisation will remain high for some time to come, that is why we have to continue with these measures," the Japan PM said, adding, "each and every one of us needs to change the way we act if we are to contain the virus's spread." However, PM Suga said the restrictions will be lifted before March 7 in prefectures where the virus situation improves. Japan's government has insisted the Olympic games will go ahead as planned in July after it was postponed last year as the pandemic took hold worldwide. The country's Parliament had passed a new law strengthening enforcement of its virus restrictions which included fine on bars and restaurants which defy closure request with just five months left for the pandemic-postponed summer Olympics in Tokyo. Japan currently has over 390,000 coronavirus cases and 5,832 fatalities as it grapples with the virus.

Ahead of Olympics, survey finds COVID-19 infections in Tokyo may have jumped nine-fold

A Singaporean woman, who had contracted the COVID-19 in March when she was pregnant, has now given birth to a baby with antibodies against the virus. The latest result now offered a new debate on whether the infection can be transfer from mother to child.

Singapore : Baby born with Coronavirus antibody

Israel's Defence Ministry has released more information now on the newly isolated COVID-19 antibody. Earlier the Defence Minister has called the development a significant breakthrough in finding a cure for COVID-19. Watch report.

What makes Israel's breakthrough significant ? | COVID-19 antibody | Coronavirus Pandemic

In the absence of a<a href="https://www.wionews.com/world/not-allergic-to-any-investigation-but-top-priority-to-fight-win-against-covid-19-china-297005"> COVID-19 </a>vaccine, antibody drugs are being touted as the next best thing.&nbsp;

<a href="https://www.wionews.com/world/most-americans-would-take-coronavirus-vaccine-if-deemed-safe-reuters-poll-296938">Also Read:&nbsp;Most Americans would take coronavirus vaccine if deemed safe</a>

Antibodies are created by our body's immune system. Scientists can harvest and then isolate them from a recovered patient's body. Israel and the Netherlands have had success in doing it.

Once antibodies are isolated, their genetic formula can be studied and replicated on a mass scale. The human body creates hundreds of antibodies - each specific to different pathogens.

It defeats the foreign cells by latching on to their surface and disables it. The physical shape and size of antibodies are quite crucial if the proportions are off, the antibodies will not be effective.

However, they are different from vaccines, antibody drugs are a cure, they cannot offer immunity to a population that has not been infected.

Vaccines on the other hand are preventive in nature. Antibody drugs bind themselves to infected cells upon injection.&nbsp;

While vaccines involve infecting the population with weak or inactivated virus samples, antibody drugs stimulate the immune system to attack the infected cells.

In the case of vaccines, the body creates antibodies by itself to fight the inactivated virus samples. They essentially work as a dress rehearsal, so that the body is ready for a full-blown infection.

Vaccines also take a longer time to develop, by conservative estimates it takes at least one year for a fool-proof vaccine to be deploid. However, antibody drugs can be developed in a matter of months as proven by institutes in Israel and the Netherlands.

And finally, vaccines generally have universal deployability. Most people can get vaccinated unless they are allergic to the formula but antibody treatments are advised only for infected patients and high-risk population groups.

In the absence of a COVID-19 vaccine, antibody drugs are being touted as the next best thing. Also Read: Most Americans would take coronavirus vaccine if deemed safe Antibodies are created by our body's immune system.

In the absence of a COVID-19 vaccine, antibody drugs are being touted as the next best thing. Also Read: Most Americans would take coronavirus vaccine if deemed safe Antibodies are created by our body's immune system. Scientists can harvest and then isolate them from a recovered patient's body. Israel and the Netherlands have had success in doing it. Once antibodies are isolated, their genetic formula can be studied and replicated on a mass scale. The human body creates hundreds of antibodies - each specific to different pathogens. It defeats the foreign cells by latching on to their surface and disables it. The physical shape and size of antibodies are quite crucial if the proportions are off, the antibodies will not be effective. However, they are different from vaccines, antibody drugs are a cure, they cannot offer immunity to a population that has not been infected. Vaccines on the other hand are preventive in nature. Antibody drugs bind themselves to infected cells upon injection. While vaccines involve infecting the population with weak or inactivated virus samples, antibody drugs stimulate the immune system to attack the infected cells. In the case of vaccines, the body creates antibodies by itself to fight the inactivated virus samples. They essentially work as a dress rehearsal, so that the body is ready for a full-blown infection. Vaccines also take a longer time to develop, by conservative estimates it takes at least one year for a fool-proof vaccine to be deploid. However, antibody drugs can be developed in a matter of months as proven by institutes in Israel and the Netherlands. And finally, vaccines generally have universal deployability. Most people can get vaccinated unless they are allergic to the formula but antibody treatments are advised only for infected patients and high-risk population groups.

How antibody drugs are different from vaccines

Antibody drugs are in the news nowadays and in the absence of a COVID-19 vaccine, they are being doubted as the next best thing. Watch report.

How are antibody drugs developed? Race to find a cure for COVID-19

antibody

Antibody, News on Antibody, stories on Antibody, articles on Antibody, Antibody stories at Wion, Antibody news, Antibody latest news